Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more

Edoardo G. Giannini, Monica Basso, Vincenzo Savarino, Antonino Picciotto

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Elderly patients with chronic hepatitis C virus (HCV) infection represent an understudied population, and little is known regarding the predictive factors for sustained virological response (SVR) to antiviral therapy in these patients. Aims: To evaluate the efficacy of pegylated interferon (PEG-IFN) and ribavirin therapy in chronic HCV patients aged 65 years, and identify pre- and on-treatment predictors of SVR. Methods: We studied 57 patients aged ≥65 years who underwent PEG-IFN and ribavirin treatment, evaluating the SVR rate and its association with pre-treatment demographic, clinical, biochemical, and virological parameters. Furthermore, we assessed whether 12-week serum HCV-RNA assessment might predict SVR. Results: A SVR was obtained in 25 patients (45%). The only pre-treatment predictor of SVR was HCV genotype 2 and 3 (P = 0.02). A positive serum HCV-RNA or a decline in viral load ≤2log 10 at week 12 had 100% negative predictive value for SVR. No major liver-related events or deaths occurred during therapy. Treatment was discontinued due to side effects-mainly cardiovascular-in 10 patients (17%). Conclusion: Pre- and on-treatment virological parameters can be used to identify elderly patients who are more likely to obtain a SVR to standard-of-care antiviral therapy for chronic HCV infection.

Original languageEnglish
Pages (from-to)3193-3199
Number of pages7
JournalDigestive Diseases and Sciences
Volume55
Issue number11
DOIs
Publication statusPublished - Nov 2010

Keywords

  • Elderly
  • Hepatitis C virus
  • Pegylated interferon
  • Ribavirin
  • Sustained virological response

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Fingerprint Dive into the research topics of 'Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more'. Together they form a unique fingerprint.

Cite this